Crossject SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0011716265
EUR
2.09
0.04 (1.95%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Operating profit has grown by an annual rate -9.83% of over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at times
2

Flat results in Dec 24

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 114 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-5.53

stock-summary
Return on Equity

540.46%

stock-summary
Price to Book

-55.72

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
22.8%
0%
22.8%
6 Months
17.42%
0%
17.42%
1 Year
10.89%
0%
10.89%
2 Years
-53.05%
0%
-53.05%
3 Years
-39.86%
0%
-39.86%
4 Years
-18.57%
0%
-18.57%
5 Years
-35.29%
0%
-35.29%

Crossject SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-9.83%
EBIT to Interest (avg)
-12.31
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-3.10
Sales to Capital Employed (avg)
0.04
Tax Ratio
18.09%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-55.95
EV to EBIT
-9.80
EV to EBITDA
-15.95
EV to Capital Employed
13.57
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-138.48%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Crossject SA"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is -90.00% vs 11.11% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 23.21% vs -3.70% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "1.00",
          "chgp": "-90.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.10",
          "val2": "-8.00",
          "chgp": "-26.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.30",
          "chgp": "66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.60",
          "val2": "-11.20",
          "chgp": "23.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-100,448.30%",
          "val2": "-13,865.80%",
          "chgp": "-8,658.25%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
0.10
1.00
-90.00%
Operating Profit (PBDIT) excl Other Income
-10.10
-8.00
-26.25%
Interest
0.50
0.30
66.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-8.60
-11.20
23.21%
Operating Profit Margin (Excl OI)
-100,448.30%
-13,865.80%
-8,658.25%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is -90.00% vs 11.11% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 23.21% vs -3.70% in Dec 2022

stock-summaryCompany CV
About Crossject SA stock-summary
stock-summary
Crossject SA
Pharmaceuticals & Biotechnology
Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject’s first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
Company Coordinates stock-summary
Company Details
Parc Mazen-Sully, 6 Rue Pauline Kergomard DIJON None : 21000
stock-summary
Tel: 33 3 80549850
stock-summary
Registrar Details